A systematic review of worldwide observational studies, including studies from the UK, suggests that persistence and adherence rates with oral bisphosphonates are wide ranging, relatively low and reduce over time. Several factors were found to affect this, with higher persistence rates seen in people taking fewer medicines and those taking weekly bisphosphonates rather than daily. This ‘real-world evidence’ emphasises the need to support people in their medicines choices to agree a plan that is based on their own circumstances, values and preferences. The NICE decision support tool on bisphosphonates for treating osteoporosis can help inform this discussion. Also of note is that the NICE guideline on multimorbidity recommends discussing stopping bisphosphonates after 3 years.
This link will take you to the medicines evidence commentary featured in the NICE Medicines Awareness Weekly. Medicines evidence commentaries help contextualise important new evidence, highlighting areas that could signal a change in clinical practice. It does not constitute formal NICE guidance.